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CHAPTER 26 
The Potential of Organ on Chip Technology for 
Replacing Animal Testing 
Malcolm Wilkinson 
Chief Executive Officer, Kirkstall Ltd., Rotherham, United Kingdom 
malcolm. wilkinson@kirkstallcom 
1 What Is Organ on a Chip Technology? 
The term organ on a chip is used to describe the latest stage of development of 
in vitro cell culture technology. Figure 26.1 shows its steady development since 
the 1960s. Each step forward has improved our ability to model human-clinical 
response to new drugs or therapies and has enabled safety risk assessment of 
existing cosmetics, personal care products, or other chemicals in the environ­
ment. Scientific evidence that the predictive power of in vitro tests is superior 
to the use of animals will trigger a major shift in the way that medical research, 
in many areas, is carried out. In this emerging field, some researchers also refer 
to organ on a chip as a microphysiological system. As yet, there are few agreed 
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In this chapter, the following definitions are used: 
2D cell culture. This is the conventional plating of cells in a plastic or glass 
plate, such as a petri dish, that contains the liquid culture media. In this for­
mat, the cells basal side is in contact with the base wall (glass or plastic); and 
the top or apical side is in contact with the media. A major limitation of this 
method is that cell-to-cell contact is very limited. The cell-culture dish can be 
a classic petri dish or, more likely, one of the highly-miniature versions known 
as microtiter plates. These have been scaled from 6 wells to 24, 96, 384, or even 
1,024, configured as regular arrays in a way that allows robotic equipment to 
load cells and media and sample media for analysis. 
3D cell culture. Having recognized the limitation of 2D cell culture, many 
approaches have been developed to increase the proportion of cell-to-cell con­
tact to create a more physiologically relevant model of the structure of tissue 
in the human body. Cells can be provided with a soft or rigid matrix or scaffold 
in which to grow. Many cells have a natural tendency to adhere to the cell­
culture dish plastic; but if the plastic is coated with a low adhesion surface, 
then the cells can clump together to form spheroids containing between 1,000 
and 10,000 cells. There are now several well-established commercial systems 
for producing spheroids in microtiter plates. The main limitation with this 
method is that cells in the center of larger spheroids are starved of oxygen and 
media and become necrotic. 
Peifusion. In the human body the vascular network links organs and trans­
ports oxygen and nutrients to the cells. It is also a vital communication high­
way for metabolic signaling between tissues. A major current goal of advanced 
in vitro models is to be able to recapitulate the physiological interactions bet­
ween tissues in the body connected by the bloodstream. This has enormous 
potential, as it will enable studies on specific two-way or higher-order organ­
to-organ and tissue interactions. Perfusion or flow of media across the cell cul­
ture is a first step in realizing this objective. Unfortunately, the flow of media 
past cells can induce flow stress, if the flow is higher than the cells might expe­
rience in the body. Hence, control of flow rate is critical. Optimized flow levels 
( which vary from tissue to tissue) can remove the necrosis in spheroids of tis­
sue slices and upregulate cell activity back to levels observed in freshly isolated 
human primary cells (Vinci et al., 2011). 
Organoids. In vitro culture of whole human organs is difficult and expen­
sive. An intense research effort is underway to see if the main functions of a 
whole organ can be replicated by a much smaller number of cells, perhaps as 
few as 10,000. When provided with the right physical, biochemical, and other 
cues, these cells will often spontaneously differentiate into a morphology that 
can replicate the features of tissue in specific organs. These small samples 
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of biological material are known as organoids. One example is hepatocytes, 
where bile ducts form (Ramachandran et al., 2015). 
Organ on a chip. This is a commonly used term in the popular press that 
would benefit from a clearer definition. The term chip is borrowed from the 
semiconductor industry and is a shortening of the term microchip, which is 
a small (typically fingernail-sized) crystal of silicon that contains millions of 
transistor circuits. The implication is that biological circuits will be capable of 
similar scaling in complexity. Unfortunately, the laws of physics apply. Biologi­
cal cells and liquid fluids do not continue to function correctly as the size is 
reduced. This is in stark contrast to electrons on transistor circuits, which oper­
ate faster and use less power as they are scaled to smaller geometries. Another 
feature of microelectronic chips is that they are manufactured thousands at a 
time on a large wafer of silicon, which is one reason why the cost per-chip can 
be very low. In contrast, organs on a chip are currently manufactured singly or 
in small batches. There is very little standardization in the manufacturing pro­
cesses used between the different laboratories making them, apart from the 
widespread use of silicone, a flexible rubber-like material, to mold the small 
channels. The chips in this case are typically 2 cm or more per side (i.e., much 
larger than silicon chips); and many have fluid connections glued in place to 
allow cell-culture media or test chemicals to be passed over the cells under 
culture. 
Organ on a plate. This is a larger format approach than organ on a chip and 
typically has multiple cell-culture chambers molded in a plastic plate. The flu­
id connections between different chambers can be formed as part of the plate 
or added by connecting flexible tubing, as in the Quasi Vivo® Interconnected 
Cell Culture System (Yoon et al., 2015). The plastic plate is often designed to 
meet the industry standard format for 6 well or 24 well to facilitate handling by 
robotic equipment. Such multi-chamber plates can be used to connect differ­
ent cell types or run multiple replicates in the same flow system. An integrated 
systemic view can, thus, be constructed piecewise; and, in the Quasi Vivo® ad­
vanced cell culture flow systems, allometry can be used to set up physiolog­
ically-relevant connected culture models of biotransformation, distribution, 
adsorption, and gas exchange (Haycock, Ahluwalia and Wilkinson, 2014). 
Microphysiological system (MPS). This terminology was first used by the De­
fense Advanced Research Projects Agency (DARPA) in the United States that 
launched the MPS program of research. MPS research aims to develop a re­
configurable platform that permits simultaneous study of 10 or more in vitro 
physiological systems, arranged in any sequence. The goal is to design a flex­
ible, user-friendly, and reliable platform that will allow biological components 
to interact in a physiologically-relevant manner and will sustain the resident 
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tissues for up to four weeks. Researchers developing the in vitro mimics aim to 
demonstrate that the engineered tissues function together to reproduce each 
of the human physiological systems. As these system mimics are integrated 
into a platform of increasing complexity, researchers must demonstrate that 
the platform reproduces the physiologically-relevant crosstalk between the 
systems that normally occurs in humans. To validate its behavior, and its po­
tential value for evaluating drugs and vaccines, test compounds with known 
effects in humans will be applied to the platform. The effects that the test com­
pounds have on the physiological system mimics will then be extrapolated to 
humans via computer modeling and compared to the health effects previously 
observed in humans. Many of the current organ on a chip developments are 
targeted to meet the requirements of the DARPA program. 
2 The Opportunity for Better in vitro Methods 
Although technological capability has now reached the point where multiple 
cell types can be cultured together in a single miniature plate, it is important to 
recognize that routine testing of chemical or drug safety lags behind the state 
of the art by many years. It is only now, after 10 years in development, that 3D 
cell culture, in the form of spheroids, is being used routinely by industry. How­
ever, 2D cell culture, in 96 or 384 well plates, is still the dominant technology. 
Considerable evidence of the benefits of any new technique has to be accumu­
lated before industry will adopt it, and it takes even longer before regulatory 
bodies accept new methods. 
One of the driving forces behind the development of the microtiter plate, 
with 96, 384, or even 1,536 small cavities for cell culture, has been the need to 
screen very large numbers of chemical compounds for safety or, in the case 
of the pharmaceutical industry, for their potential as drugs. Historically, the 
pharmaceutical industry has had access to tens of thousands of chemical com­
pounds that may, potentially, be active drugs. Hence, the need for a very simple 
go /no go test that could quickly screen a large number of compounds to a more 
manageable number. Despite the high throughput of tests using microtiter 
plates, the High Throughput Screening (HTS) assays give very little, if any, in­
formation about mechanisms of action. Current HTS assays are very narrowly 
focused ( e.g., receptor binding) and usually use animal-derived cells or subcel­
lular components. If advanced HTS could use human cells/components, they 
may reveal much more information. Because HTS in vitro testing has only pro­
vided poor prediction of what is likely to happen in clinical trials, regulatory 
bodies still demand testing of drug candidates on animals. However, because 
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FIGURE 26.2 Summary of the drug development process. 
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testing on animals is so expensive, pharmaceutical companies try to screen 
out the more obvious failures before that stage. The drug development process 
is shown in Figure 26.2. HTS is mainly used in the first stage of drug discovery 
when the number of candidate drugs to be screened may be as high as 10,000. 
There is still considerable opportunity to improve the efficiency of this pro­
cess despite the billions of dollars invested in it each year. The primary moti­
vation for industry is the immense waste of resources, because around go% 
of the drug candidates that enter clinical trials fail to reach the market (Mul­
lard, 2016). This is because both current in vitro testing and animal methods are 
poor predictors of what will happen in clinical trials. It is this need for a more 
predictive method that is driving the development of organ on a chip and or­
gan on a plate technology. 
3 The Functional Requirement for Improved in vitro Methods 
There is a growing body of knowledge that shows that the use of animal 
cells in in vitro testing is a factor in the poor performance of current meth­
ods. Even the use of whole animal models does not replicate what happens 
in the human body, so it is hardly surprising that animal cells placed in an in 
vitro environment will also give misleading results ( Chandrasekera and Pip­
pin, 2014; Cook, Clerk and Sugden, 2009; Mestas and Hughes, 2004; Potashkin, 
Blume and Runkle, 2011). 
The choice to use animal cells is often driven by convenience rather than 
scientific reasons for further discussion see Redmond, 2019, Chapter 27. Hu­
man cells are difficult to obtain, often come from a single diseased patient, 
and are not representative of a larger pool of donors. Cell lines derived from 
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human cells are more readily available, but there are issues with the cell lin­
eage. Tumor-derived cell lines readily proliferate; but their functionality may 
be quite different from healthy tissue; and their very robustness may be a prob­
lem, if we are trying to achieve a sensitive test for toxicity of a chemical or drug. 
Even when a representative supply of cells has been secured, there are other 
reasons why the models can be inadequate. Current research indicates that 2D 
static cell culture ( no flow of media) is not as good at predicting toxicity as 3D 
cell culture (Eglen, 2017). There is also a growing body of evidence that perfu­
sion (flow) of media over or through the cells produces a better prediction of 
IC50 (half maximal inhibitory concentration) levels of drug toxicity than static 
medium (Davidge and Bishop, 2017 ). 
Using this wealth of research, we can set out a list of requirements that 
should be met by any advanced in vitro method, including organ on a chip: 
Biological requirements 
- Use of human cells 
- Culture conditions that produce physiologically relevant organoid models 
- Connected organoids, so that the system models the whole organism 
- Long-term culture/homeostasis for repeat-dose testing or low clearance 
compounds 
Practical requirements 
- Easy to use and fast to set up in the laboratory 
- Robust/repeatable across multiple laboratories 
- No air bubbles disrupting flow or blockages caused by biological material 
Scale requirements 
- Better HTS tests and high-content methods to replace animals 
- Ability to test thousands of compounds for improving HTS assays 
- Ability to test tens of compounds and replace hundreds of animals used in 
preclinical screening 
Economical requirements 
- Capital and consumable cost lower than animal testing 
- Even lower cost per test to replace HTS. 
The last points in this list suggest that the market for advanced cell culture 
could become segmented into high throughput approaches and high-content 
(lower throughput) methods. 
4 History and Current Status of Organ on a Chip Methods 
The concept of combining of microtechnology and biology to reconstitute the 
physiological and mechanical functions of human organs is not a new one. 
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Michael Shuler at Cornell University was one of its pioneers. In 1994, Shuler 
filed patents on a macro scale in vitro system for the physiological and meta­
bolic evaluation of substances for use in living beings. The system included one 
or more cell culture chambers, each containing cells in a culture medium and 
a gas-liquid exchange device for contacting the culture medium with oxygen­
containing gas. By 2003, Shuler was developing a micro-scale version (Park and 
Shuler, 2003), which was closely followed by Arti Ahluwalia at the University of 
Pisa (Ahluwalia, 2004), who filed her first patent in 2004. These pioneers were 
then followed by a surge of researchers, including Luke Lee at the University of 
California, Linda Griffith at the Massachusetts Institute of Technology, Donald 
Ingber at Harvard University, Shuichi Takayama at the University of Michigan, 
and many more. Sung and Shuler (2010) provide an excellent review of this 
area of research. 
Progress between 2004 and 2014 was slow because of the significant tech­
nical challenges encountered in the application of microfluidics to biological 
systems. Few of the start-up companies that emerged from the early academic 
laboratories managed to get products to market. Despite these early setbacks 
there has been a resurgence of interest in the area following significant fund­
ing allocated to organ on a chip developers by the us DARPA and the us Na­
tional Institutes of Health (NIH), who have awarded us$140 million and us$76 
million, respectively, over a 5-year period, to support developments. In parallel, 
technology developers have raised more than us$8o million since 2012 with 
equity investors. These investments caught the attention of market analysts; 
and in 2016, the first market forecast specifically aimed at this sector was pub­
lished (Accuray Research LLP, 2016). In 2017, a more detailed analysis of the 
market was provided by Yole Research ( Clerk and Villien, 2017 ). Yole's analysts 
estimated the combined sales of organ on a chip devices and service offerings 
at no more than us$7.5 million in 2016. 
Most companies in this area are spin offs from university laboratories and 
are currently developing their organ on a chip devices through projects spon­
sored by industrial players. Pharmaceutical and cosmetics companies are in­
terested in the emerging technology but remain skeptical about its potential in 
the short term. Given the experience with 3D spheroid technology, it could be 
many years before the technology is ready for widespread adoption. However, 
the belief that such technologies could become a multibillion dollar market 
in the mid- to long-term future has the potential to accelerate progress, given 
the billions of dollars they could help the pharmaceutical industry save every 
year. Ethical concerns are also one of the potential drivers at the heart of this 
new market. Around the world, at least 115 million vertebrates are estimated 
to be used for scientific purposes annually (Taylor et al., 2008). Many of these 
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FIGURE 26 . 3  Leading contenders in the race to develop organs on a chip and organs on a 
plate. 
animals could be replaced by alternative methods, which may include some 
elements of microfluidic technology. 
Some of the leading developments in organ on a chip are summarized in 
Figure 26.3. 
Summarizing the current developments, we can observe that there is lit­
tle standardization. Each team is developing its own approach, with its own 
unique technology. The players are mainly start-up companies commercializ­
ing prototypes developed in the local universities. There is widespread use of 
silicone plastic to fabricate chambers and channels; but Mimetas and Kirk­
stall have opted to use acrylic-type plastic that can be injection molded and, 
hence, is amenable to volume production. There are widely differing cham­
ber and plate sizes. Hurel, C N  Bio, and Mimetas use 96 well plate size; TissUse 
and Kirkstall use 24 well plate size; and Wyss/Emulate has custom plates for 
each organ. Another point of divergence is the way that cell-culture media is 
fed into the chambers and over the cells. Pneumatic, peristaltic, and syringe 
pumps, as well as gravity fed flow, are all in use. Although some of the cell­
culture chambers look simple, many require complex control systems to set 
up and maintain the temperature and gas ambient environment. Mimetas, 
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TissUse, and Kirkstall have all opted to use conventional cell-culture incuba­
tors into which their systems are loaded. 
Returning to the functional requirements listed in the previous section, 
we can gage how well each of the contenders are faring in their endeavor to 
achieve a technology that will be capable of replacing some of the animal test­
ing in the drug discovery process. 
4.1 Biological Requirements 
Animal cells may be easier to obtain and keep alive than human primary cells, 
but they are not moving us forward. Human tumor-derived cell lines are easy 
to culture but are not representative of healthy tissue. Human-induced plurip­
otent stem cells (hiPscs) look promising but are currently expensive and need 
long, complex protocols to create the differentiated cells needed for organ 
models. Human donor tissue could be considered the gold standard, but cryo­
preservation is needed to store tissue from donors to match the time window 
for experiments. Unfortunately, cryopreservation compromises the function of 
the cells. Esch, Bahinski and Huh (2015) provide a review of the cell types used 
in organ on chip models. 
4.2 Practical Requirements 
In order for any new technology to achieve regulatory acceptance, it must 
demonstrate that it is a robust and repeatable method. Many of the organ on 
a chip methods are a long way from this goal. They are so complex to set up 
and operate that they are only running in the host developer's laboratory and 
offered as a service. In contrast, Kirkstall has designed its Quasi Vivo® organ 
on a plate platform to be easy to use and fast to set up in the laboratory. It is 
well on the way to demonstrating that it can be robust and repeatable across 
multiple laboratories with a current academic-user base of more than 70 
universities. 
4.3 Scale Requirements 
Figure 26.2 shows the different points in the drug discovery and development 
process where organs on a chip could be used. There is a clear divergence be­
tween the requirement to screen thousands of compounds and improve HTS 
assays, and the lower throughput needs to test in-depth tens of compounds 
and replace hundreds of animals used in preclinical screening. Most of the 
current organ on chip developments have indicated that the former is their 
commercial goal. In contrast, TissUse and Kirkstall have opted for 24 well plate 
size chambers that should be more suited to the latter and a focus on animal 
replacement. 
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Since so few of the organ on a chip projects have offered products to the mar­
ket as yet, it is difficult to assess the likely costs involved. Many of the technolo­
gies are suitable for scaling to volume production and so, in theory, should be 
capable of meeting customers' expectations on cost. The economics of animal 
replacement have been thoroughly researched by Hartung and his team at 
Johns Hopkins University (Bottini and Hartung, 2009). The cost targets (capi­
tal and consumable cost) to replace animal testing are probably easier to meet 
than those to replace existing HTS. 
5 Barriers and Drivers for Change 
There is a clear market need for improvements in the drug discovery and de­
velopment process, and this is validated by the eagerness with which phar­
maceutical and cosmetics companies are evaluating new technologies, one 
of which is organ on a chip and in silica modeling another. However, inertia 
among researchers is recognized as a barrier to moving away from existing ani­
mal methods (Innovate UK, 2015). In addition, they are conservative and will 
need time to complete evaluation, validation, and adoption of the technology. 
Regulatory approval, if required, will take even longer. Apart from the techni­
cal challenges yet to be solved, the start-up companies that are championing 
the new methods face commercial issues. Some have raised significant equity 
investment to complement government grants and customer-sponsored re­
search and development projects. Government grants to individual compa­
nies and to organizations supporting the 3Rs have been particularly helpful. 
In the United Kingdom, such grants have been part of the Innovate UK's road­
map to support the development of non-animal technologies (Innovate UK, 
2015). 
The current worldwide market for animal testing is estimated to be in ex­
cess of us$30 billion (Bottini and Hartung, 2010 ); and it is most likely that the 
companies involved in that market (including contract research organizations 
offering animal testing) will fight hard to defend their current business, de­
spite the ethical and scientific pressures for change. It is not only businesses 
that will fight to defend the status quo. Many academic careers are based on 
animal models, and it is not easy to make changes late in a career. In contrast, 
early-career researchers will be highly motivated to learn about new methods, 
but the peer review system for awarding grants will make it tough for them 
to get approval for ground-breaking and disruptive ideas. Centers of excel­
lence are emerging to support animal replacement technologies. The Center 
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for Alternatives to Animal Testing (CAAT) at Johns Hopkins University in the 
us was one of the first and now has a satellite at the University of Konstanz in 
Germany. The UK has the Animal Replacement Centre of Excellence (ARC ) at 
Queen Mary University, London; and Canada has just launched the Canadian 
Centre for Alternatives to Animal Methods ( c CAAM) at the University of Wind­
sor, Ontario. These centers will act as nuclei for further awareness creation, 
research funding, technology evaluation, and industry support. Their most ef­
fective action may be to train a new generation of researchers who are aware of 
the disruptive technology and are willing to become agents for change. 
The conservatism of regulators is often cited as one of the most difficult 
barriers to overcome (Innovate UK, 2015) .  The production of an overwhelming 
body of scientific evidence may be the best long-term approach. After all, the 
regulators' role is to protect the public from the risks of exposure to harmful 
drugs and chemicals. In the absence of good in vitro models and data, they will 
always revert to what their colleagues have done for years before them, i.e., 
insist on animal testing. In the short term, there are other ways to introduce 
the new technology that do not need regulatory approval but utilize in vitro 
tests in parallel to reduce the number of drug candidates before they enter the 
expensive animal and clinical-testing phases. In vitro methods are then effec­
tively being used to cause compounds to fail early, and the potential economic 
savings are immense. Additionally, as in vitro assays are implemented, they will 
be validated by improved success in subsequent clinical trials. 
Figure 26.4 shows a representative comparison of the economic benefits of 
using advanced in vitro testing to reduce the number of drug compounds go­
ing forward into animal testing. By testing 25 compounds and eliminating 10 
that have shown some adverse activity, only 15 go forward. The potential saving 
is u s $226 million, justifying a significant investment in the additional in vitro 
tests. This approach does not need regulatory approval because animal testing 
will still be used in the later stages, albeit on a reduced number of compounds. 
With these potential savings per drug candidate reaching the market, Yole 
Research's projection that the organ on a chip market could reach between 
us $6o million and u s $176 million by 2022 does not seem unreasonable. 
6 A Strategy for Accelerating the Paradigm Change Away 
from Animal Use 
The previous sections described the technology, market opportunity, status of 
current developments, and barriers and incentives for change. Is there any way 
that we can accelerate this process and speed the adoption of methods that 
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Traditional Developement Using Improved in Vitro with OOC 
Target Discovery and Validation Target Discovery and Validation 
25 Target to Lead $2sM 25 Target to Lead $25M 
20 Lead to Hit $50M Lead to Hit $47M ooc Cl) 15 
Optimisation $150M Used ;::1 Optimisation $107M 0 15 10 
Preclinical $6oM Preclinical $ 35M 0 12 7 
Phase 1 0 ... 
... (I.) 4 
(I.) 9 $ 135M ..0 
..0 e 
e Phase 2 ;::1 3 ;::1 5 $ 200M z z 
2 Phase 3 $300M 
Total cost $920M Total cost $694M 
F I GURE 2 6 . 4  Potential cost benefits of using advanced in vitro methods, such as organ on a 
chip (ooc). 
will save the lives of countless animals and reduce their suffering? Many years 
of research in the high technology industry show us that incremental change 
is much easier to push forward than disruptive change. Clearly, the full replace­
ment of animals is a disruptive change. The candidate technology presented 
here is also disruptive, as it is not a natural outgrowth of existing biology or 
microtechnology but a fusion of the two. The technical challenges are enor­
mous and require a multidisciplinary effort from biologists, pharmacologists, 
statisticians, computer modelers, plastic material and fabrication engineers, 
and many other experts. It is interesting that the challenge of bringing together 
scientists from different disciplines to work on, so-called, grand challenges has 
been addressed in several universities. Pisa University created the Centro Piag­
gio and Sheffield University the Kroto Centre with this express goal. Technical 
brilliance is not enough. The new technology has to be translated into a sus­
tainable business, and that takes a whole different skill set. Entrepreneurship 
is needed. 
The roadmap and strategy presented in Figure 26.5 describes an innovative 
approach to synthesizing disruptive change from a number of smaller, almost 
incremental steps. The foundation starts with good science from a few opinion 
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• Early interest 
• Contract research organization joint development 
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FI GURE 2 6 . 5  A roadmap and strategy for  accelerating the adoption of alternative methods, 
showing parallel adoption in academia and industrial research. 
leaders in the academic sector but leads on to the creation of centers of excel­
lence that eventually drive widespread adoption of the new paradigm through 
academe. It is important to note that academic research accounts for about 
half of the total number of animals used in the UK. Industry adoption follows 
but is slower at first because of the need for extensive evidence to support 
claims of superiority for the emerging new technology. The early evidence 
comes from academics followed by the development of robust protocols by 
contract research organizations. The pharmacological industry is increasingly 
using contract research organizations to do validation and development work 
that may previously have been done in their own research and development 
laboratories. 
Much of the current interest and excitement about organ on a chip technol­
ogy is fueled by marketing hype and will soon be replaced by disillusionment 
unless practical working systems are delivered. Many of the venture capitalists 
investing in organ on a chip will expect immense financial return from the 
10% of their portfolio that succeed. There are some very exciting technology 
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developments under way. Although some of these are several years away from 
the market, there is no doubt that within the next 3 to 5 years, we will see the 
start of a significant shift away from the use of animals. 
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